Targeted Muscle Reinnervation for Limb Amputation to Avoid Neuroma and Phantom Limb Pain in Patients Treated at a Pediatric Hospital

Kim A Bjorklund, John Alexander, Kirsten Tulchin-Francis, Natasha S Yanes, Satbir Singh, Ian Valerio, Kevin Klingele, Thomas Scharschmidt, Kim A Bjorklund, John Alexander, Kirsten Tulchin-Francis, Natasha S Yanes, Satbir Singh, Ian Valerio, Kevin Klingele, Thomas Scharschmidt

Abstract

Amputees frequently experience chronic neuroma-related residual limb and phantom limb pain (PLP). Targeted muscle reinnervation (TMR) transfers transected nerves to nearby motor nerves to promote healing and prevent neuroma formation and PLP. The purpose of this study was to report outcomes of TMR in a series of children and young adults treated at a pediatric hospital.

Methods: Patients undergoing major limb amputation with TMR were included with minimum one year follow-up and completed questionnaires. Primary clinical outcomes included incidence of symptomatic neuromas, PLP, residual limb pain, narcotic use, and neuromodulator use. A follow-up phone survey was conducted assessing five pediatric Patient Reported Outcomes Measurement Information System (PROMIS) metrics adapted to assess residual limb and PLP.

Results: Nine patients (seven male and two female patients, avg. age = 16.83 ± 7.16 years) were eligible. Average time between surgery and phone follow-up was 21.3 ± 9.8 months. Average PROMIS Pediatric t-scores for measures of pain behavior, interference, quality-affective, and quality-sensory for both PLP and residual limb pain were nearly 1 standard deviation lower than the United States general pediatric population. One patient developed a symptomatic neuroma 1 year after surgery.

Conclusions: Compared with an adult patient sample reported by Valerio et al, our TMR patients at Nationwide Children's Hospital (NCH) showed similar PLP PROMIS t-scores in pain behavior (50.1 versus 43.9) and pain interference (40.7 versus 45.6). Both pediatric and adult populations had similar residual limb pain including PROMIS pain behavior (36.7 adult versus 38.6 pediatric) and pain interference (40.7 adult versus 42.7 pediatric). TMR at the time of amputation is feasible, safe, and should be considered in the pediatric population.

Conflict of interest statement

The authors have no financial interest to declare in relation to the content of this article.

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.

References

    1. Oh C, Carlsen BT. New innovations in targeted muscle reinnervation: a critical analysis review. JBJS reviews. 2019;7:e3.
    1. Robert RS, Ottaviani G, Huh WW, et al. . Psychosocial and functional outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery and amputation. Pediatr Blood Cancer. 2010;54:990–999.
    1. DeMoss P, Ramsey LH, Karlson CW. Phantom limb pain in pediatric oncology. Front Neurol. 2018;9:219.
    1. Buchheit T, Van de Ven T, Hsia HL, et al. . Pain phenotypes and associated clinical risk factors following traumatic amputation: results from veterans integrated pain evaluation research (VIPER). Pain Med. 2016;17:149–161.
    1. Krane EJ, Heller LB. The prevalence of phantom sensation and pain in pediatric amputees. J Pain Symptom Manage. 1995;10:21–29.
    1. Pet MA, Ko JH, Friedly JL, et al. . Traction neurectomy for treatment of painful residual limb neuroma in lower extremity amputees. J Orthop Trauma. 2015;29:e321–e325.
    1. Anghelescu DL, Kelly CN, Steen BD, et al. . Mirror therapy for phantom limb pain at a pediatric oncology institution. Rehabil Oncol. 2016;34:104–110
    1. Huse E, Larbig W, Flor H, et al. . The effect of opioids on phantom limb pain and cortical reorganization. Pain. 2001;90:47–55.
    1. Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev. 2016;10:CD006380.
    1. Robinson LR, Czerniecki JM, Ehde DM, et al. . Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Arch Phys Med Rehabil. 2004;85:1–6.
    1. Nikolajsen L, Finnerup NB, Kramp S, et al. . A randomized study of the effects of gabapentin on postamputation pain. Anesthesiology. 2006;105:1008–1015.
    1. Wang X, Yi Y, Tang D, et al. . Gabapentin as an adjuvant therapy for prevention of acute phantom-limb pain in pediatric patients undergoing amputation for malignant bone tumors: a prospective double-blind randomized controlled trial. J Pain Symptom Manage. 2018;55:721–727.
    1. Kuiken TA, Dumanian GA, Lipschutz RD, et al. . The use of targeted muscle reinnervation for improved myoelectric prosthesis control in a bilateral shoulder disarticulation amputee. Prosthet Orthot Int. 2004;28:245–253.
    1. Souza JM, Cheesborough JE, Ko JH, et al. . Targeted muscle reinnervation: a novel approach to postamputation neuroma pain. Clin Orthop Relat Res. 2014;472:2984–2990.
    1. McNamara CT, Iorio ML. Targeted muscle reinnervation: outcomes in treating chronic pain secondary to extremity amputation and phantom limb syndrome. J Reconstr Microsurg. 2020;36:235–240.
    1. Valerio IL, Dumanian GA, Jordan SW, et al. . Preemptive treatment of phantom and residual limb pain with targeted muscle reinnervation at the time of major limb amputation. J Am Coll Surg. 2019;228:217–226.
    1. Zuo KJ, Willand MP, Ho ES, et al. . Targeted muscle reinnervation: considerations for future implementation in adolescents and younger children. Plast Reconstr Surg. 2018;141:1447–1458.
    1. Pires GR, Moss WD, Ormiston LD, et al. . Targeted muscle reinnervation in children: a case report and brief overview of the literature. Plast Reconstr Surg Glob Open. 2021;9:e3986.
    1. Alexander JH, Jordan SW, West JM, et al. . Targeted muscle reinnervation in oncologic amputees: Early experience of a novel institutional protocol. J Surg Oncol. 2019;120:348–358.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe